Literature DB >> 18401015

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology.

Alba A Brandes1, Alicia Tosoni, Federica Spagnolli, Giampiero Frezza, Marco Leonardi, Fabio Calbucci, Enrico Franceschi.   

Abstract

Although radionecrosis has been exhaustively described in depth in the neurooncological literature, its diagnosis is still a challenging issue because its radiological pattern is frequently indistinguishable from that of tumor recurrence. This review discusses the causes of radionecrosis and the potential effect of adjuvant chemotherapy concomitant with radiotherapy on its rate and onset. The potential pitfalls in clinical studies attempting to make a differential diagnosis between radionecrosis and disease progression are also discussed.

Entities:  

Mesh:

Year:  2008        PMID: 18401015      PMCID: PMC2563059          DOI: 10.1215/15228517-2008-008

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  43 in total

1.  Radiotherapy of the brain in elderly patients. Contra:.

Authors:  A A Brandes; A Rigon; S Monfardini
Journal:  Eur J Cancer       Date:  2000-03       Impact factor: 9.162

2.  Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy.

Authors:  H P Schlemmer; P Bachert; M Henze; R Buslei; K K Herfarth; J Debus; G van Kaick
Journal:  Neuroradiology       Date:  2002-03       Impact factor: 2.804

Review 3.  Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.

Authors:  M C Y de Wit; H G de Bruin; W Eijkenboom; P A E Sillevis Smitt; M J van den Bent
Journal:  Neurology       Date:  2004-08-10       Impact factor: 9.910

4.  Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas.

Authors:  M Castillo; J K Smith; L Kwock; K Wilber
Journal:  AJNR Am J Neuroradiol       Date:  2001-01       Impact factor: 3.825

5.  Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas.

Authors:  V A Levin; W K A Yung; J Bruner; A Kyritsis; N Leeds; M J Gleason; K R Hess; C A Meyers; S A Ictech; E Chang; M H Maor
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-05-01       Impact factor: 7.038

6.  Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy.

Authors:  H P Schlemmer; P Bachert; K K Herfarth; I Zuna; J Debus; G van Kaick
Journal:  AJNR Am J Neuroradiol       Date:  2001-08       Impact factor: 3.825

7.  Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis.

Authors:  Jack P Rock; David Hearshen; Lisa Scarpace; David Croteau; Jorge Gutierrez; James L Fisher; Mark L Rosenblum; Tom Mikkelsen
Journal:  Neurosurgery       Date:  2002-10       Impact factor: 4.654

8.  Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis.

Authors:  Jack P Rock; Lisa Scarpace; David Hearshen; Jorge Gutierrez; James L Fisher; Mark Rosenblum; Tom Mikkelsen
Journal:  Neurosurgery       Date:  2004-05       Impact factor: 4.654

9.  Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme.

Authors:  Nathan S Floyd; Shiao Y Woo; Bin S Teh; Charlotte Prado; Wei-Yuan Mai; Todd Trask; Philip L Gildenberg; Paul Holoye; Mark E Augspurger; L Steven Carpenter; Hsin H Lu; J Kam Chiu; Walter H Grant; E Brian Butler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

10.  Cerebral necrosis following irradiation and chemotherapy for metastatic choriocarcinoma.

Authors:  R A Pratt; G Di Chiro; J C Weed
Journal:  Surg Neurol       Date:  1977-03
View more
  111 in total

1.  Bevacizumab: radiation combination produces restricted diffusion on brain MRI.

Authors:  John R Hesselink; Matthew J Barkovich; Tyler M Seibert; Nikdokht Farid; Karra A Muller; Kevin T Murphy; Santosh Kesari
Journal:  CNS Oncol       Date:  2014

2.  Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.

Authors:  Jerrold L Boxerman; Zheng Zhang; Yair Safriel; Mykol Larvie; Bradley S Snyder; Rajan Jain; T Linda Chi; A Gregory Sorensen; Mark R Gilbert; Daniel P Barboriak
Journal:  Neuro Oncol       Date:  2013-06-19       Impact factor: 12.300

3.  SLC7A11 Overexpression in Glioblastoma Is Associated with Increased Cancer Stem Cell-Like Properties.

Authors:  Monika D Polewski; Rosyli F Reveron-Thornton; Gregory A Cherryholmes; Georgi K Marinov; Karen S Aboody
Journal:  Stem Cells Dev       Date:  2017-07-27       Impact factor: 3.272

4.  Preclinical MRI: Studies of the irradiated brain.

Authors:  Joel R Garbow; Christina I Tsien; Scott C Beeman
Journal:  J Magn Reson       Date:  2018-04-26       Impact factor: 2.229

5.  Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.

Authors:  Morad Nasseri; Seymur Gahramanov; Joao Prola Netto; Rongwei Fu; Leslie L Muldoon; Csanad Varallyay; Bronwyn E Hamilton; Edward A Neuwelt
Journal:  Neuro Oncol       Date:  2014-02-11       Impact factor: 12.300

6.  EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.

Authors:  Enrico Franceschi; Roger Stupp; Martin J van den Bent; Carla van Herpen; Florence Laigle Donadey; Thierry Gorlia; Monika Hegi; Benoit Lhermitte; Lewis C Strauss; Anouk Allgeier; Denis Lacombe; Alba A Brandes
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

7.  Outcome of Adult Brain Tumor Consortium (ABTC) prospective dose-finding trials of I-125 balloon brachytherapy in high-grade gliomas: challenges in clinical trial design and technology development when MRI treatment effect and recurrence appear similar.

Authors:  L R Kleinberg; V Stieber; T Mikkelsen; K Judy; J Weingart; G Barnett; J Olson; S Desideri; X Ye; S Grossman
Journal:  J Radiat Oncol       Date:  2015-08-05

8.  Seizures during the management of high-grade gliomas: clinical relevance to disease progression.

Authors:  Young-Hoon Kim; Chul-Kee Park; Tae Min Kim; Seung Hong Choi; Yu Jung Kim; Byung Se Choi; Jung Ho Han; Se-Hoon Lee; Chae-Yong Kim; In Ah Kim; Dae Seog Heo; Il Han Kim; Dong Gyu Kim; Hee-Won Jung
Journal:  J Neurooncol       Date:  2013-03-04       Impact factor: 4.130

9.  Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.

Authors:  Melissa A Prah; Mona M Al-Gizawiy; Wade M Mueller; Elizabeth J Cochran; Raymond G Hoffmann; Jennifer M Connelly; Kathleen M Schmainda
Journal:  J Neurooncol       Date:  2017-09-12       Impact factor: 4.130

10.  Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

Authors:  Kathleen M Schmainda; Zheng Zhang; Melissa Prah; Bradley S Snyder; Mark R Gilbert; A Gregory Sorensen; Daniel P Barboriak; Jerrold L Boxerman
Journal:  Neuro Oncol       Date:  2015-02-02       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.